• In the past quarter, 10x Genomics reported Q1 results that surpassed revenue and earnings estimates, even as revenue saw a slight year-on-year decline, and management reaffirmed full-year guidance.
• Management also highlighted strong uptake of newer single cell and spatial consumables like FLEX Apex and Atara, with robust Atara preorders helping offset delays in purchases of older spatial instruments.
• Now we’ll examine how this earnings beat and reaffirmed guidance might influence 10x Genomics’ existing investment narrative built around product expansion.

Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

10x Genomics Investment Narrative Recap

To own 10x Genomics, you need to believe its expanding portfolio in single cell and spatial biology can turn today’s unprofitable, research-focused model into a durable consumables and software franchise. The latest earnings beat and reaffirmed guidance support confidence in product uptake as the key near term catalyst, but do not remove the central risk that constrained research funding and cautious capital budgets could still weigh on instrument demand and overall revenue stability.

The recent launch of the Atara spatial platform is especially relevant here. Management pointed to strong Atara preorders and growing volumes of new consumables like FLEX Apex during Q1, which helped counter softer demand for older spatial instruments. For investors watching whether product refreshes can offset funding and CapEx headwinds, Atara’s early traction provides a practical test of that thesis in the coming quarters.

Yet even with growing Atara and FLEX adoption, you should still be aware that constrained academic and government funding could...

10x Genomics' narrative projects $709.8 million revenue and $110.2 million earnings by 2029. This requires 3.4% yearly revenue growth and a $153.7 million earnings increase from -$43.5 million today.

Uncover how 10x Genomics' forecasts yield a $20.14 fair value, a 15% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting revenue to reach about US$750 million with a return to positive earnings, but this Q1 beat and strong Atara consumables momentum could either support that faster inflection or highlight how exposed those forecasts are to softer instrument demand and research funding risks.

Explore 3 other fair value estimates on 10x Genomics - why the stock might be worth as much as 44% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your 10x Genomics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free 10x Genomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 10x Genomics' overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.